Literature DB >> 21804558

Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells.

Sonia Feau1, Ramon Arens, Susan Togher, Stephen P Schoenberger.   

Abstract

Two competing theories have been put forward to explain the role of CD4(+) T cells in priming CD8(+) memory T cells: one proposes paracrine secretion of interleukin 2 (IL-2); the other proposes the activation of antigen-presenting cells (APCs) via the costimulatory molecule CD40 and its ligand CD40L. We investigated the requirement for IL-2 by the relevant three cell types in vivo and found that CD8(+) T cells, rather than CD4(+) T cells or dendritic cells (DCs), produced the IL-2 necessary for CD8(+) T cell memory. Il2(-/-) CD4(+) T cells were able to provide help only if their ability to transmit signals via CD40L was intact. Our findings reconcile contradictory elements implicit in each model noted above by showing that CD4(+) T cells activate APCs through a CD40L-dependent mechanism to enable autocrine production of IL-2 in CD8(+) memory T cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21804558      PMCID: PMC3388550          DOI: 10.1038/ni.2079

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  40 in total

1.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

2.  Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming.

Authors:  Francesca Granucci; Sonia Feau; Véronique Angeli; François Trottein; Paola Ricciardi-Castagnoli
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 3.  The role of programming in memory T-cell development.

Authors:  David Masopust; Susan M Kaech; E John Wherry; Rafi Ahmed
Journal:  Curr Opin Immunol       Date:  2004-04       Impact factor: 7.486

4.  Role of self-peptides in positively selecting the T-cell repertoire.

Authors:  J Nikolić-Zugić; M J Bevan
Journal:  Nature       Date:  1990-03-01       Impact factor: 49.962

5.  Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response.

Authors:  N A Mitchison; C O'Malley
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

6.  Immune responses in interleukin-2-deficient mice.

Authors:  T M Kündig; H Schorle; M F Bachmann; H Hengartner; R M Zinkernagel; I Horak
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

Review 7.  Tolerance, not immunity, crucially depends on IL-2.

Authors:  Thomas R Malek; Allison L Bayer
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

8.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.

Authors:  H Schorle; T Holtschke; T Hünig; A Schimpl; I Horak
Journal:  Nature       Date:  1991-08-15       Impact factor: 49.962

9.  A contribution of mouse dendritic cell-derived IL-2 for NK cell activation.

Authors:  Francesca Granucci; Ivan Zanoni; Norman Pavelka; Serani L H Van Dommelen; Christopher E Andoniou; Filippo Belardelli; Mariapia A Degli Esposti; Paola Ricciardi-Castagnoli
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

View more
  116 in total

1.  4th Aegean Conference on the Crossroads between Innate and Adaptive Immunity.

Authors:  Stephen P Schoenberger; Bali Pulendran; Peter D Katsikis
Journal:  Nat Immunol       Date:  2011-12-16       Impact factor: 25.606

2.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Authors:  Eric F Zhu; Shuning A Gai; Cary F Opel; Byron H Kwan; Rishi Surana; Martin C Mihm; Monique J Kauke; Kelly D Moynihan; Alessandro Angelini; Robert T Williams; Matthias T Stephan; Jacob S Kim; Michael B Yaffe; Darrell J Irvine; Louis M Weiner; Glenn Dranoff; K Dane Wittrup
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

3.  Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Authors:  Scott M Krummey; Ryan J Martinez; Rakieb Andargachew; Danya Liu; Maylene Wagener; Jacob E Kohlmeier; Brian D Evavold; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

4.  CD40 is required for protective immunity against liver stage Plasmodium infection.

Authors:  Sara A Murray; Isaac Mohar; Jessica L Miller; Katherine J Brempelis; Ashley M Vaughan; Stefan H I Kappe; Ian N Crispe
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

Review 5.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

6.  Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions.

Authors:  Sarah Eickhoff; Anna Brewitz; Michael Y Gerner; Frederick Klauschen; Karl Komander; Hiroaki Hemmi; Natalio Garbi; Tsuneyasu Kaisho; Ronald Nathan Germain; Wolfgang Kastenmüller
Journal:  Cell       Date:  2015-08-18       Impact factor: 41.582

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Ikaros imposes a barrier to CD8+ T cell differentiation by restricting autocrine IL-2 production.

Authors:  Shaun O'Brien; Rajan M Thomas; Gerald B Wertheim; Fuqin Zhang; Hao Shen; Andrew D Wells
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet.

Authors:  Annie Xin; Frederick Masson; Yang Liao; Simon Preston; Tianxia Guan; Renee Gloury; Moshe Olshansky; Jian-Xin Lin; Peng Li; Terence P Speed; Gordon K Smyth; Matthias Ernst; Warren J Leonard; Marc Pellegrini; Susan M Kaech; Stephen L Nutt; Wei Shi; Gabrielle T Belz; Axel Kallies
Journal:  Nat Immunol       Date:  2016-03-07       Impact factor: 25.606

10.  Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.

Authors:  Nicholas M Provine; Rafael A Larocca; Malika Aid; Pablo Penaloza-MacMaster; Alexander Badamchi-Zadeh; Erica N Borducchi; Kathleen B Yates; Peter Abbink; Marinela Kirilova; David Ng'ang'a; Jonathan Bramson; W Nicholas Haining; Dan H Barouch
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.